



Medplus Health Services Limited

July 21, 2026

The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001
BSE Scrip Code: 543427

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block,
Bandra - Kurla Complex
Bandra (East), Mumbai – 400051
NSE Symbol: MEDPLUS

Dear Sir/Madam,

Sub: Outcome of Board meeting under SEBI (Listing Obligation and Disclosure requirements) Regulations 2015 (Listing Regulations)

In furtherance to our letter dated July 07, 2026, and pursuant to Regulation 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), the Board of Directors of the Company, at their meeting held today i.e., July 21, 2026, approved/noted the followings:

1. The Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026, along with Limited Review Report received from the M/s B S R and Co, Chartered Accountants (Firm registration Number 128510W) Statutory Auditors of the Company.

A copy of the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026 along with Limited Review Report thereon is enclosed as **Annexure-A**.

2. CAPEX Plan for setting up of Food Park including Cold Press Oil Extraction Unit at Hyderabad, Telangana by Optival Health Solutions Private Limited (Material Subsidiary).

The proposed project entails CAPEX of approximately **Rs. 400 million**, towards development of land, construction of building, procurement and installation of unit and machinery, utilities, filling and packing lines, and other project-related capital expenditure.

3. CAPEX Plan for setting up a **Concierge Health & Wellness Services Facility** at Hyderabad, Telangana. The proposed service facility is intended to provide preventive healthcare, diagnostics, specialist consultations and wellness services through a subscription-based membership model.

The estimated investment for the project is approximately **Rs. 1150 million**, comprising capital expenditure of **Rs. 900 million**.

4. Based on the recommendation of Nomination and Remuneration Committee, the Board approved the appointment of Mr. Shrenik Soni (M. No.: F12400) as the Company Secretary and Compliance Officer (Key Managerial Personnel) of the Company w.e.f July 21, 2026, subject to such terms and conditions as approved by the Board of Directors.



040-6724 6724



Medplus Health Services Limited

In view of the above and pursuant to Regulation 30(5) of the SEBI LODR Regulations the contact details of Mr. Shrenik Soni, authorised as KMP under the Company's Policy on criteria for determining the materiality for disclosure of events or information with effect from July 21, 2026 are as follows:

Particulars	Details
Company	MedPlus Health Services Limited
Name	Mr. Shrenik Soni
Designation	Company Secretary and Compliance Officer (Key Managerial Personnel)
Contact Number	040-6724-6724
Email	shrenik.s@medplusindia.com
Address	H. No: 11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, (Moosapet), Kukatpally, Hyderabad - 500 037, Telangana, India.

The details as required under Regulation 30 of the SEBI Listing Regulations read along with SEBI Master Circular No. H0/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026 are given as **Annexure-B**.

The meeting commenced at 02:00 PM and concluded at 4:30 PM.

The same will be available on the website of the Company at www.medplusindia.com and also on the websites of BSE Limited and National Stock Exchange of India Ltd. viz. www.bseindia.com and www.nseindia.com respectively.

Kindly take the same on records.

For MedPlus Health Services Limited

Gangadi Madhukar Reddy
Managing Director and CEO
(DIN: 00098097)

Encl: a/a

 040-6724 6724

Limited Review Report on unaudited consolidated financial results of MedPlus Health Services Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**To the Board of Directors of MedPlus Health Services Limited**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of MedPlus Health Services Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2026 ("the Statement") (in which are included interim financial information of Medplus Employees Benefit Trust ("Trust")), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement.
5. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Principal Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East), Mumbai - 400063

Limited Review Report (Continued)

MedPlus Health Services Limited

7. We did not review the interim financial results of 2 subsidiaries included in the Statement, whose interim financial results reflect total revenues (before consolidation adjustments) of Rs. 1,923.18 million, total net profit after tax (before consolidation adjustments) of Rs. 10.72 million and total comprehensive income (before consolidation adjustments) of Rs 10.72 million, for the quarter ended 30 June 2026, as considered in the Statement. These interim financial results have been reviewed by other auditor whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

8. The Statement includes the interim financial results of 9 Subsidiaries which have not been reviewed, whose interim financial results reflect total revenues (before consolidation adjustments) of Rs. 770.75 million, total net profit after tax (before consolidation adjustments) of Rs. 9.74 million and total comprehensive income (before consolidation adjustments) of Rs. 9.74 million, for the quarter ended 30 June 2026, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial results are not material to the Group.

Our conclusion is not modified in respect of this matter.

For **B S R and Co**

Chartered Accountants

Firm's Registration No.: 128510W



R. Vivek

Partner

Hyderabad

21 July 2026

Membership No.: 225161

UDIN: 26225161WJIWHY1534

Limited Review Report (Continued)

MedPlus Health Services Limited

Annexure I


List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	MedPlus Health Services Limited	Holding Company
2	Optival Health Solutions Private Limited	Subsidiary
3	Nova Sud Pharmaceuticals Private Limited	Subsidiary
4	Wynclark Pharmaceuticals Private Limited	Subsidiary
5	Kalyani Meditimes Private Limited	Subsidiary
6	Clearancekart Private Limited	Subsidiary
7	Sai Sridhar Pharma Private Limited	Subsidiary
8	Venkata Krishna Enterprises Private Limited	Subsidiary
9	Shri Banashankari Pharma Private Limited	Subsidiary
10	Deccan Medisales Private Limited	Subsidiary
11	Sidson Pharma Distributors Private Limited	Subsidiary
12	MedPlus Insurance Brokers Private Limited	Subsidiary
13	MedPlus Foundation	Subsidiary

Statement of Unaudited Consolidated Financial Results for the Quarter ended June 30, 2026

(Rs. in Millions)

S. No	Particulars	Quarter ended			Year ended
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		Unaudited	Audited refer note 4	Unaudited	Audited
I	Income				
	Revenue from operations	18,796.00	18,643.85	15,426.34	68,924.66
	Other income	198.26	205.95	150.19	713.24
	Total income	18,994.26	18,849.80	15,576.53	69,637.90
	Expenses				
	Cost of materials consumed	206.64	256.25	191.80	887.30
	Purchases of stock-in-trade	14,590.48	13,951.21	10,529.48	50,304.70
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(604.23)	(498.02)	676.08	(345.93)
	Employee benefits expense	2,419.06	2,381.17	2,004.41	8,845.28
	Finance costs	332.70	334.80	273.65	1,204.93
II	Depreciation and amortisation expense	779.21	759.47	656.18	2,828.68
	Other expenses	851.63	861.50	717.27	3,159.64
II	Total expenses	18,575.49	18,046.38	15,048.87	66,884.60
III	Profit before tax (I-II)	418.77	803.42	527.66	2,753.30
IV	Tax expense				
	- Current tax expense	114.87	223.91	143.92	776.63
	- Deferred tax benefit	(27.77)	(60.22)	(39.69)	(219.39)
IV	Total tax expense	87.10	163.69	104.23	557.24
V	Net Profit after tax (III-IV)	331.67	639.73	423.43	2,196.06
VI	Other comprehensive income (OCI)				
	(i) Items that will not be reclassified to profit or loss				
	- Re-measurement gain on employee defined benefit plan	-	26.91	-	26.91
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	(5.20)	-	(5.20)
VI	Other comprehensive income for the period/year, net of tax	-	21.71	-	21.71
VII	Total comprehensive income for the period/year (V+VI)	331.67	661.44	423.43	2,217.77
VIII	Profit for the period/year attributable to:				
	Shareholders of the Company	331.76	639.83	423.58	2,196.49
	Non-controlling interest	(0.09)	(0.10)	(0.15)	(0.43)
IX	Other comprehensive income for the period/year attributable to:	331.67	639.73	423.43	2,196.06
	Shareholders of the Company	-	21.71	-	21.71
	Non-controlling interest	-	0.00	-	0.00
X	Total comprehensive income attributable to:	-	21.71	-	21.71
	Shareholders of the Company	331.76	661.54	423.58	2,218.20
	Non-controlling interest	(0.09)	(0.10)	(0.15)	(0.43)
XI	Paid-up Capital	331.67	661.44	423.43	2,217.77
	Equity Share Capital	240.27	240.11	239.49	240.11
	Other Equity				19,513.48
XIII	Earnings per equity share (refer note 5)				
	Basic EPS (In absolute Rs)	2.76	5.33	3.54	18.33
	Diluted EPS (In absolute Rs)	2.76	5.33	3.53	18.29
XIV	Face value per share				
	Equity shares (In absolute Rs)	2.00	2.00	2.00	2.00



Segment information under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
for the Quarter ended June 30, 2026

(Rs. In Millions)

Particulars	Quarter Ended			Year Ended
	June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
	Unaudited	Audited refer note 4	Unaudited	Audited
1. Segment revenue				
a. Retail	18,423.92	18,289.76	15,121.19	67,601.06
b. Diagnostic services	370.76	347.80	302.90	1,309.87
c. Others	1.32	6.29	2.25	13.73
Total revenue from operations	18,796.00	18,643.85	15,426.34	68,924.66
2. Segment results profit / (loss)				
a. Retail	315.63	705.23	449.54	2,388.11
b. Diagnostic services	23.24	9.64	0.77	17.40
c. Others	(0.34)	4.29	1.07	6.72
Total	338.53	719.16	451.38	2,412.23
Add/(Less): Unallocable Finance cost	(0.05)	(0.20)	(0.27)	(0.49)
Add: Unallocable other income	80.29	84.46	76.55	341.56
Total profit before tax	418.77	803.42	527.66	2,753.30
3. Segment assets				
a. Retail	31,919.79	31,097.74	26,783.08	31,097.74
b. Diagnostic services	1,380.92	1,377.34	1,427.40	1,377.34
c. Others	3.63	9.12	5.93	9.12
d. Unallocated	7,126.66	6,841.06	6,284.53	6,841.06
Total assets	40,431.00	39,325.26	34,500.94	39,325.26
4. Segment liabilities				
a. Retail	19,247.99	18,566.31	15,669.74	18,566.31
b. Diagnostic services	1,074.70	1,011.00	983.75	1,011.00
c. Others	1.40	1.41	1.57	1.41
Total liabilities	20,324.09	19,578.72	16,655.06	19,578.72

27




Notes to the consolidated financial results:

1. The above unaudited consolidated financial results of MedPlus Health Services Limited ('The Company') and its subsidiaries (together referred as 'The Group') have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("listing regulations") from time to time. These unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on July 21, 2026. These financial results have been subjected to limited review by the Statutory Auditors of the Company and the auditors have expressed and issued an unmodified review report on the same.
2. During the year ended March 31, 2026, the Central Government of India notified the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020, collectively referred to as the 'New Labour Codes', effective from November 21, 2025 primarily impacting the wage definition to be considered for the purpose of defined benefit obligation relating to gratuity and defined benefit contribution relating to leave encashment.

As a result of this plan amendment, the Group's defined benefit obligation and defined benefit contribution increased by Rs. 34.26 million and Rs. 31.06 million respectively during the year ended March 31, 2026. A corresponding past service cost was recognized in the statement of profit and loss in the previous year. The Group continues to monitor the Central / State Rules as notified and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.
3. During the period, the Company incorporated a wholly owned subsidiary, MedPlus Foundation, on May 06, 2026. The financial information of the said subsidiary has been consolidated in these financial results from the date of incorporation, in accordance with the applicable accounting standards.
4. The consolidated figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the respective financial year.
5. The earnings per equity share for the quarters are not annualised.
6. The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com.

For and on behalf of the Board of Directors of
MedPlus Health Services Limited



G. Madhukar Reddy

Managing Director & Chief Executive Officer

DIN: 00098097

Place: Hyderabad

Date: July 21, 2026





Limited Review Report on unaudited standalone financial results of MedPlus Health Services Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**To the Board of Directors of MedPlus Health Services Limited**

1. We have reviewed the accompanying Statement of unaudited standalone financial results of MedPlus Health Services Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2026 ("the Statement") (in which are included interim financial information of Medplus Employees Benefit Trust ("Trust")).
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it

Principal Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East), Mumbai - 400063

Page 1 of 2



B S R and Co


Limited Review Report (Continued)
MedPlus Health Services Limited

contains any material misstatement.

For **B S R and Co**

Chartered Accountants

Firm's Registration No.: 128510W



R. Vivek

Partner

Hyderabad

21 July 2026

Membership No.: 225161

UDIN: 26225161DSUSAW8482

(Rs. in Millions)

S. No	Particulars	Quarter ended			Year ended
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		Unaudited	Audited refer note 4	Unaudited	Audited
	Income				
	Revenue from operations	2,226.43	2,480.36	1,838.81	8,605.66
	Other income	32.66	24.86	26.45	107.66
I	Total income	2,259.09	2,505.22	1,865.26	8,713.32
	Expenses				
	Cost of materials consumed	189.21	181.36	191.80	812.41
	Purchases of stock-in-trade	1,496.24	1,736.30	1,175.20	5,703.85
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(5.09)	1.35	4.98	7.19
	Employee benefits expense	137.19	147.11	122.64	542.99
	Finance costs	22.21	13.97	21.52	83.14
	Depreciation and amortisation expense	69.62	54.35	67.21	263.86
	Other expenses	119.54	140.22	105.13	468.15
II	Total expenses	2,028.92	2,274.66	1,688.48	7,881.59
III	Profit before tax (I-II)	230.17	230.56	176.78	831.73
	Tax expense				
	- Current tax expense	64.85	67.95	46.91	226.14
	- Deferred tax benefit	(9.19)	(4.11)	(5.46)	(18.53)
IV	Total tax expense	55.66	63.84	41.45	207.61
V	Net Profit after tax (III-IV)	174.51	166.72	135.33	624.12
	Other comprehensive income				
	(i) Items that will not be reclassified to profit or loss				
	- Re-measurement gain on employee defined benefit plan	-	4.94	-	4.94
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	(1.19)	-	(1.19)
VI	Other comprehensive income for the period / year, net of tax	-	3.75	-	3.75
VII	Total comprehensive income for the period / year (V+VI)	174.51	170.47	135.33	627.87
VIII	Paid-up capital				
	Equity share capital	240.27	240.11	239.49	240.11
IX	Other Equity				12,921.02
X	Earnings per equity share (refer note 5)				
	Basic (In absolute Rs.)	1.45	1.39	1.13	5.21
	Diluted (In absolute Rs.)	1.45	1.39	1.13	5.20
XI	Face value per share				
	Equity shares (In absolute Rs.)	2.00	2.00	2.00	2.00

2

Handwritten signature



Notes to the standalone financial results:

1. The above unaudited standalone financial results of MedPlus Health Services Limited ('The Company') have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("listing regulations") from time to time. These unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on July 21, 2026. These financial results have been subjected to limited review by the Statutory Auditors of the Company and the auditors have expressed and issued an unmodified review report on the same.
2. During the year ended March 31, 2026, the Central Government of India notified the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020, collectively referred to as the 'New Labour Codes', effective from November 21, 2025 primarily impacting the wage definition to be considered for the purpose of defined benefit obligation relating to gratuity and defined benefit contribution relating to leave encashment.

As a result of this plan amendment, the Company's defined benefit obligation and defined benefit contribution increased by Rs. 1.58 million and Rs. 0.47 million respectively during the year ended March 31, 2026. A corresponding past service cost was recognized in the statement of profit and loss in the previous year. The Company continues to monitor the Central / State Rules as notified and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.
3. As per Ind AS 108 'Operating segments', the Company has disclosed the segment information as part of the consolidated financial results.
4. The standalone figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the respective financial year.
5. The earnings per equity share for the quarters are not annualised.
6. The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com.

For and on behalf of the Board of Directors of
MedPlus Health Services Limited

G. Madhukar Reddy

Managing Director & Chief Executive Officer

DIN: 00098097



Place: Hyderabad

Date: July 21, 2026

[Handwritten signature]

ANNEXURE B

Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/ I/3762/2026 dated January 30, 2026. Changes in directors, key managerial personnel, senior management:

Sr. No	Disclosure Requirement	Details
1.	Name of the KMP	Mr. Shrenik Soni (M. No.: F12400)
2.	Reason for Change, viz Appointment, Resignation, Removal, Death or Otherwise	Appointment of Mr. Shrenik Soni as Company Secretary and Compliance Officer
3.	Date of Appointment/ Cessation & term of appointment	Effective from July 21 st , 2026
4.	Brief Profile (in case of appointment of a director)	Mr. Shrenik Soni (M. No.: F12400) is a Fellow Member of Institute of Company Secretaries of India (ICSI) and holds a dual specialization Post-Graduation Degree of Master of Business Administration (MBA), from Osmania University. He is a seasoned Corporate Governance professional with more than 9 years of experience in Corporate secretarial, legal and compliance functions across sectors such as pharmaceuticals, manufacturing and retail. Mr. Shrenik Soni has handled various responsibilities during his tenure with previous organisations viz. Board processes and corporate governance, fundraising through various means, ESOPs, listing of Equity Shares, regulatory interface, legal/secretarial due diligence, demerger, IPO readiness, acquisition/takeover, corporate restructuring, compliance management systems, various compliance requirements under SEBI Regulations, Companies Act and other corporate laws, liasoning with government authorities and other regulatory authorities/agency, etc. Prior to joining MedPlus, he was associated with HRV Pharma, SUVEN Life Sciences and DUKES Group as Company Secretary.
5.	Disclosure of relationships between directors (in case of appointment of Director)	Not Applicable